ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

ISTH 2022 Congress

Venous Thromboembolism

Theme Navigation

  • ISTH 2022 Congress
    • Venous Thromboembolism
      • Antiphospholipid Syndrome
      • Artificial Valves
      • Cancer Associated Thrombosis
      • Genetic Risk Factors of Thrombosis
      • Post-thrombotic Syndrome
      • Thrombophilia
      • Visceral Vein Thrombosis
      • VTE Diagnosis
      • VTE Epidemiology
      • VTE Prophylaxis
      • VTE Treatment

Abstract Number: VPB1381

A Case Series In Pregnant Women Receiving Therapeutic LMWH, Is Monitoring Anti-Xa Levels Necessary?

S. Chong1, P. Liew2, V. Selvaratnam3, S. Tan2

Abstract Number: OC 56.1

A Cross-Ancestry Meta-Analysis of Venous Thromboembolism Genetic Associations

F. Thibord1, D. Klarin2, D. Chasman3, M. Teder-Laving4, E. Goode5, K. Hveem6, A. Martinez-Perez7, J. Emmerich8, X. Jouven9, K. Ito10, G. Cuellar Partida11, J. Haessler12, J. Hansen13, A. van Hylckama Vlieg14, P. Morange15, C. Kabrhel16, D. Tregouet17, S. Damrauer18, A. Johnson19, N. Smith20

Abstract Number: PB0933

A randomized clinical trial to evaluate the effect of rosuvastatin with enoxaparin on circulating tissue factor extracellular vesicles following ovarian cancer surgery

A. Osataphan1, R. Patell2, R. Rosovsky3, P. Elavalakanar1, A. Bregar4, A. Ramos4, L. Garrett1, S. Ren5, D. Neuberg5, M. Shea1, J. Zwicker2

Abstract Number: VPB1378

A systematic review of factors associated with non-adherence to the use of coumarin derivatives or direct oral anticoagulants

W. Freitas Nunes De Sousa1, N. Sernizon Guimarães1, C. Costa Viana1, P. Machado1, A. Fonseca Medeiros1, M. Sousa Vianna1, R. Pedra De Souza1, C. Margotto Bartollo1, M. Praxedes2, M. Parreiras Martins1

Abstract Number: PB1322

A ten-year Australian experience of splanchnic vein thrombosis

J. Oktaviana1, B. Lui1, P. Ho2, H. Lim1

Abstract Number: OC 48.2

A TEN-YEAR REVIEW OF THE IMPACT OF TRANSITION FROM WARFARIN TO DIRECT ORAL ANTICOAGULANT– HAS VTE TREATMENT BECOME SAFER?

B. Lui1, B. Wee1, A. Kwok2, J. Lai2, Z. Khattak3, C. Donarelli3, P. Ho4, H. Lim1

Abstract Number: PB1365

A Tool Integrated in the Electronic Health Record to Guide Proper Decision-Making Regarding Peri-Endoscopic Anticoagulant Use

A. Plender1, L. Faber2, S. Graumans1

Abstract Number: PB0927

Abelacimab does not influence the effects of two commonly used antiplatelet agents in vitro

Y. Khder1, S. Cote2, P. Hoffmann3, D. Bloomfield4

Abstract Number: PB0925

Abelacimab has no effect on platelet aggregation induced by TRAP-6 and collagen

Y. Khder1, S. Cote2, P. Hoffmann3, D. Bloomfield4

Abstract Number: VPB1344

ABO blood group and factor viii level as risk factors for idiopathic venous thromboembolism.

A. Diaz1, M. Vazquez2, M. Ordoñez2, F. Neria2, J. Cachá2, M. Gomez2

Abstract Number: VPB1314

ABO blood group as an additional risk factor for venous thromboembolism

E. Ristovska1, T. Makarovska Bojadjieva1, S. Useini1, E. Velkova1, E. Petkovic1, V. Dejanova Ilijevska1, J. Trajkova1, L. Ismaili2, M. Tashkovska3

Abstract Number: PB0447

Adherence and persistence to Direct Oral Anticoagulants (DOACs) in the community following newly diagnosed Venous Thromboembolism (VTE) – a pharmacy-linkage study

C. Dix1, H. Bortz2, M. da Gama3, M. Treloar3, M. Reynolds3, T. Day4, H. Tran5

Abstract Number: PB0960

Adherence to thrombophilia testing guidelines and accuracy of thrombophilia work-up: a single-center cross sectional study

K. Vrotniakaite-Bajerciene1, F. Schmidli2, K. Jalowiec2, H. Broughton2, J. Schneider2, A. Haynes3, J. Brodard2, A. Rovo2, J. Kremer Hovinga4, A. Angelillo-Scherrer2

Abstract Number: PB0972

Adjusted D-dimer cutoff levels to rule out pulmonary embolism in patients hospitalized for COPD exacerbation: results from the SLICE trial

D. Jimenez1, C. Rodriguez1, L. Jara-Palomares2, E. Tabernero3, A. Tenes1, S. Gonzalez1, W. Briceño1, J. Lobo4, R. Morillo1, B. Bikdeli5

Abstract Number: VPB1342

Aetiological profile of inferior veina cava thrombosis

R. Ben Salah1, F. Mkaouar2, o. Frikha2, F. Frikha2, Z. bAHLOUL3

Abstract Number: OC 32.3

Anti-β2-glycoprotein I antibodies cause activated protein C resistance by interfering with Factor V cleavage at Arginine 506

T. Noordermeer1, S. Chemlal1, J. Molhoek2, R. Schutgens3, M. Limper4, P. de Groot5, J. Meijers6, R. Urbanus1

Abstract Number: VPB0944

Anticoagulant associated bleeding risk assessment model for cancer associated thrombosis patients: A systematic review

G. POENOU1, E. TOLEDANO2, H. HELFER3, L. PLAISANCE2, e. VERSINI2, N. DIAB4, S. DJENNAOUI2, I. Mahe5

Abstract Number: PB0431

Anticoagulant therapy for splanchnic vein thrombosis: an individual patient data meta-analysis

M. Candeloro1, E. Valeriani2, M. Monreal3, W. Ageno4, N. Riva5, R. Lopez Reyes6, M. Peris7, J. Beyer Westendorf8, S. Schulman9, V. Rosa10, J. LÓPEZ-NÚÑEZ11, J. Garcia-Pagan12, M. Magaz12, M. Senzolo13, A. De Gottardi14, M. Di Nisio15

Abstract Number: PB1370

Anticoagulation Control, Outcomes and Associated Factors in Patients Receiving Warfarin in Long-term care in Africa: A Systematic Review

T. Tadesse1, G. Temesgen2, D. Yadeta3, L. Chelkaba2, T. Gedif2

Abstract Number: PB0414

Antiphospholipid Syndrome-related Venous Thromboembolism: A Nationwide Study

H. Hwang1, S. Bang2, J. Lee3, S. Kim3, Y. Kim4, M. Kim5, J. Hong6, H. Yhim7

  • 1
  • 2
  • 3
  • …
  • 15
  • Next Page »

« View all themes from the ISTH 2022 Congress

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 John Wiley & Sons, Inc. All Rights Reserved.
Wiley